The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis.

ABSTRACT:

Background

Fifteen percent of patients with endometrial cancer (EC) have advanced stage disease or develop a recurrence. Progestins have been applied as systemic treatment for decades, but there is limited evidence on response prediction with biomarkers and toxicity.

Objectives

To review the response and toxicity of progestin therapy and stratify response to progesterone receptor (PR) expression and tumour grade.

Search strategy

We used the search terms 'Endometrial cancer', 'Progestins', 'Disease progression', 'Recurrence' and related terms in Pubmed, Embase and Cochrane databases.

Selection criteria

Studies on patients with advanced stage or recurrent EC treated with progestin monotherapy were included. Studies on adjuvant therapy, with fewer than ten cases a

SUBMITTER: van Weelden WJ 

PROVIDER: S-EPMC10100186 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature